Healthcare
CORMEDIX INC
Ticker: CRMD
|
Exchange: US
|
Composite FIGI: BBG000Q4BQK0
Total Alternative Signals
1signals tracked
Weighted Sentiment
+0.90weighted index
Avg Materiality Score
5.0/ 5.0 scale
Signal Distribution
1▲|0■|0▼
Alternative Data Signal Feed
Unlock Alternative Signals Feed
Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for CORMEDIX INC. Programmatic API and Webhooks available.
Earnings ReportBullish
Filing Date: 2026-06-14
Signal Event Report - FIGI BBG000Q4BQK0
CorMedix reported strong Q1 2026 financial results, including $127.4 million in net revenue and $38.6 million in net income, driven by robust DefenCath sales and higher outpatient dialysis utilization. The company was also recognized as one of the 10 Most Profitable Small Cap Stocks.
Quantitative Investment Thesis
The strong Q1 2026 earnings, particularly the significant revenue contribution from DefenCath and increased utilization, validate the company's commercial strategy and product market fit. This performance strengthens the long-term investment case, indicating sustained profitability and growth potential.
Materiality & Sentiment Scores
Sentiment: 0.9
Materiality: 5 / 5
Source Document: https://finance.yahoo.com/sectors/healthcare/articles/cormedix-inc-crmd-reports-q1-180724238.html?.tsrc=rss